| Literature DB >> 30038408 |
Michael R Filbin1, Jill E Thorsen2, James Lynch3, Trent D Gillingham2, Corey L Pasakarnis2, Roberta Capp4, Nathan I Shapiro5, Theodore Mooncai2, Peter C Hou6, Thomas Heldt3, Andrew T Reisner2.
Abstract
Feasibility of ED triage sepsis screening, before diagnostic testing has been performed, has not been established. In a retrospective, outcome-blinded chart review of a one-year cohort of ED adult septic shock patients ("derivation cohort") and three additional, non-consecutive months of all adult ED visits ("validation cohort"), we evaluated the qSOFA score, the Shock Precautions on Triage (SPoT) vital-signs criterion, and a triage concern-for-infection (tCFI) criterion based on risk factors and symptoms, to screen for sepsis. There were 19,670 ED patients in the validation cohort; 50 developed ED septic shock, of whom 60% presented without triage hypotension, and 56% presented with non-specific symptoms. The tCFI criterion improved specificity without substantial reduction of sensitivity. At triage, sepsis screens (positive qSOFA vital-signs and tCFI, or positive SPoT vital-signs and tCFI) were 28% (95% CI: 16-43%) and 56% (95% CI: 41-70%) sensitive, respectively, p < 0.01. By the conclusion of the ED stay, sensitivities were 80% (95% CI: 66-90%) and 90% (95% CI: 78-97%), p > 0.05, and specificities were 97% (95% CI: 96-97%) and 95% (95% CI: 95-96%), p < 0.001. ED patients who developed septic shock requiring vasopressors often presented normotensive with non-specific complaints, necessitating a low threshold for clinical concern-for-infection at triage.Entities:
Mesh:
Year: 2018 PMID: 30038408 PMCID: PMC6056466 DOI: 10.1038/s41598-018-29427-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Schematic of investigational sepsis screening tools. Dx = diagnosis; DDx = differential diagnosis. aMajor comorbidities: immunosuppressive therapy; active cancer; long-term institutionalization; permanent neurologic disability; chronic dialysis; congestive heart failure limiting daily function; chronic pulmonary disease with oxygen–dependence; liver disease with evidence of cirrhosis; presence of percutaneous tubes or drains; prior sepsis; or recent major surgery.
Figure 2Case examples applying SPoT and qSOFA vital-signs criteria. The SPoT Vital-Signs Criterion was positive when SBP < 100 mmHg and/or HR > SBP; the earliest time that the criterion was met is indicated by shaded boxes in the two case illustrations. The qSOFA Vital-Signs Criterion was positive at the earliest time that at least two of the three constituent conditions were met: (i) Respiratory rate ≥ 22 per min; (ii) GCS < 15; and (iii) SBP ≤ 100 mmHg.7 At any time that there was one documented vital-sign abnormality, we checked earlier in the record to see if there was prior documentation of a second vital-sign abnormality that would make the qSOFA vital-signs criterion positive; the earliest time that the criterion was met is indicated by the later of the connected solid circles in the case illustrations. The Alternative qSOFA Vital-Signs Criterion was also explored, which required at least two of the three constituent qSOFA conditions be met within the same set of documented vital signs; the earliest time that the Alternative qSOFA criterion was met is indicated by dashed circles in right-hand panel, whereas this criterion was never met in the left-hand panel. We determined that this Alternative qSOFA yielded generally reduced sensitivity and increased Time to (+) Screen, and it was therefore omitted from further investigation.
Clinical Characteristics of Septic Patients for Derivation Cohort & Validation Cohort.
| Parameter | Derivation Cohort Septic Patients (12-mo interval) | Validation Cohort Septic Patients (3-mo interval) | |
|---|---|---|---|
| (n = 141) | (n = 50) | ||
| Triage | Age, yrs, median (IQR) | 70 (58–81) | 65 (53–75) |
| Febrile (Temp > 100.4 °F) | 29 (21%) | 5 (10%) | |
| Heart Rate, bpm, median (IQR) | 104 (84–120) | 97 (78–118) | |
| Systolic Blood Pressure, mmHg, median (IQR) | 100 (76–120) | 106 (87–135) | |
| Triage SBP < 100 | 70 (50%) | 20 (40%) | |
| Triaged to Non-Acute ED Area | 25 (18%) | 3 (6%) | |
| tCFI: triage Concern for Infection | In all patients: | n = 141 | n = 50 |
| tCFI: Probable | 46 (33%) | 21 (42%) | |
| Possible | 95 (67%) | 28 (56%) | |
| Unlikely | 0 | 1 (2%) | |
| In patients with a Sepsis Risk Factor: | 135 (96%) | 44 (88%) | |
| tCFI: Probable | 42 (30%) | 19 (38%) | |
| Possible | 93 (66%) | 24 (48%) | |
| Unlikely | 0 | 1 (2%) | |
| Clinical Details | Documented SBP < 90 in ED | 135 (96%) | 47 (94%) |
| Time from Triage to SBP < 90, hours, median (IQR) | 0.7 (0.0–2.5) | 0.7 (0.1–2.1) | |
| Total IV Fluids, L, median (IQR) | 3.00 (2.00–4.00) | 2.65 (1.55–3.98) | |
| Serum Lactate, mmol/L, median (IQR) | 2.7 (1.7–3.9) | 2.6 (1.9–3.8) | |
| SOFA Score, median (IQR) | 9 (7–11) | 9 (7–12) | |
| Hospital Mortality | 38 (27%) | 15 (30%) | |
| SPoT Vitals | Met SPoT Vital-Signs Criterion in the ED | 141 (100%) | 50 (100%) |
| Time from Triage to SPoT, hours, median (IQR) | 0.0 (0.0–0.4) | 0.1 (0.0–0.8) | |
| qSOFA Vitals | Met qSOFA Vital-Signs Criterion in the ED | 127 (90%) | 43 (86%) |
| Time from Triage to qSOFAa, hours, median (IQR) | 0.6 (0.1–1.8) | 0.7 (0.1–1.4) |
aExcludes patients who never met qSOFA vital-signs criterion in ED.
Clinical Summary of Septic Patients for Validation Cohort.
| Age (yrs) | Major Comorbidities | Systemic Sx | Localizing Sx | tCFI | Triage SBP (mmHg) | Triage HR (bpm) | Triage Temp (°F) | ICU Dx |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| 27 | IBD, TPN | Fever, weakness | “Generalized” abd. pain, HA | + | 104 | 131 | 101.7 | Chole |
| 27 |
| Unresponsive |
| + | 70 | 88 | 96.4 | Pna |
| 31 | Onc | Fever | SOB | + | 98 | 160 | 105.1 | Pna |
| 44 | Onc | Fever, hypotension | +/− abd. pain | + | 100 | 137 | 97.8 | Uro |
| 46 | ESRD, C. Dif. | Weakness | Diarrhea | + | 146 | 68 | 98.4 | Colitis |
| 51 | ESLD, auto | “Chronic body pain” | Nausea, cough, SOB | + | 95 | 80 | 97.0 | Colitis vs pna |
| 53 | Major disability | Unresponsive |
| + | 90 | 97 | 98.7 | Uro |
| 54 | Onc | Weakness | Difficulty swallowing, cough | + | 180 | 113 | 98.5 | Pna |
| 55 | ESLD | Somnolent | Leg pain, bilateral leg edema | + | 108 | 65 | 97.0 | Soft tissue |
| 58 | Onc | Fever, tachycardia | None | + | 124 | 159 | 104.0 | Uro vs chole |
| 59 | Major disability | Fever | SOB | + | 125 | 122 | 97.3 | Uro |
| 65 | Major disability | Fever | Dry mouth, shoulder pain | + | 123 | 88 | 100.2 | Pna vs uro |
| 65 | COPD, CHF, C. Dif. | Lethargy | Abd. pain, diarrhea | + | 88 | 110 | 97.0 | Uro |
| 66 |
|
| SOB | + | 149 | 120 | 96.0 | Pna |
| 66 | Major disability | Fever, lethargy | SOB | + | 160 | 112 | 98.4 | Pna vs uro |
| 67 |
| Unresponsive | SOB | + | 73 | 82 | 98.0 | Pna & endo |
| 71 | None | Fever | Acute femur fx after fall | + | 101 | 83 | 98.0 | Uro |
| 81 | COPD, CAD | Confusion | Abd. pain, SOB | + | 101 | 79 | 98.2 | Peritonitis |
| 85 | Major disability | Fever, lethargy |
| + | 130 | 103 | 100.1 | Uro |
| 89 | COPD | Respiratory arrest |
| + | 87 | 114 | 94.6 | Pna |
| 94 | CHF | Fever | Cough | + | 120 | 70 | 97.2 | Pna |
|
| ||||||||
| 27 | None | Near-syncope | Breast pain & erythema, SOB |
| 87 | 144 | 99.9 | Mastitis |
| 38 | ESLD | Lethargy, confusion | “Mild” abd. pain | + | 190 | 69 | 98.0 | Chole |
| 43 | None (alcoholism) | Somnolent, confused | MODS (from OSH) |
| 133 | 109 | 96.5 | Empiric |
| 45 | ESLD | Active seizures | Hypoxia | + | 163 | 144 | 101.7 | Pna |
| 48 | Onc | None | Abd. pain, vomiting, SOB | + | 73 | 72 | 98.2 | Peritonitis |
| 50 | IBD, TPN | Weakness, falls | Abd. pain | + | 98 | 95 | 98.4 | Line |
| 53 | Active cancer, COPD | Weakness | Chest & back pain | + | 143 | 107 | 100.0 | Empiric |
| 54 | Major disability | Fever, confusion | Orthopedic cast (foot) pain | + | 109 | 118 | 102.5 | Uro |
| 56 | None (minor CVA) | Confusion, syncope | Chest pain, SOB |
| 159 | 81 | 97.0 | Empiric |
| 56 | ESLD | Weakness | Chest pain | + | 58 | 86 | 97.1 | Uro & colitis |
| 57 | Onc | Lethargy, hypotension | Hemoptysis | + | 97 | 116 | 97.4 | Empiric |
| 59 | CHF |
| SOB | + | 126 | 138 | 97.0 | Pna |
| 60 | None (alcoholism) | Hypotensive | Abd. & chest pain, EKG Δ |
| 74 | 122 | 98.0 | Odontogenic |
| 64 | ESLD | Somnolent, confused |
| + | 96 | 96 | 97.9 | Colitis vs uro |
| 67 | None | Somnolent, confused |
| + | 77 | 60 | 97.0 | Empiric |
| 67 | None | Lethargy, syncope |
| + | 103 | 68 | 86.3 | Empiric |
| 69 | ESLD | Somnolent, confused |
| + | 67 | 73 | 97.8 | Soft tissue |
| 70 | None | Lethargy, confusion | Incontinence | + | 148 | 110 | 99.4 | Soft tissue |
| 72 | COPD | Lethargy, diaphoretic |
| + | 64 | 42 | 98.0 | Empiric |
| 74 | CHF | None | Back pain, cough, SOB | + | 126 | 80 | 97.8 | Pna |
| 75 | Onc | None | “Mild” RUQ pain, nausea | + | 186 | 89 | 96.0 | Chole |
| 75 | None | Syncope | Nausea | + | 78 | 130 | 97.4 | Uro |
| 77 | Onc | Myalgias | HA, SOB | + | 79 | 71 | 97.0 | Line |
| 79 |
| PEA arrest |
| + | 129 | 116 | 97.5 | Pna |
| 79 | Major disability | Somnolent, confused |
| + | 137 | 105 | 98.2 | Uro |
| 80 | Onc | None | “Diffuse” abd. pain, SOB | + | 159 | 128 | 97.0 | Pna |
| 81 | Appi (recent) | Syncope | Diarrhea, SOB | + | 136 | 65 | 97.1 | Peritonitis |
| 84 | CHF, COPD | Somnolent | SOB | + | 111 | 77 | 96.2 | Pna |
|
| ||||||||
| 82 | None | “Dizziness” | Significant bradycardia |
| 128 | 44 | 98.0 | Urosepsis |
Clinical summary of vasopressor-dependent ED septic shock patients from validation cohort. “Unknown” indicates clinical information that ED providers were unable to obtain, e.g., patient confused or mechanically ventilated. Initial infection probability: Categorization of ED provider concern for bacterial infection prior to diagnostic testing (“likely”, “possible” or “unlikely”) based on the ED provider’s documentation. Major comorbidities: Pre-specified sepsis risk factors (see text for details); notable PMHx that was not included in the tCFI “risk factor” criteria is reported in parentheses. Onc = active cancer; major disability = physical or cognitive disability requiring services; COPD = chronic obstructive pulmonary disease; CAD = coronary artery disease; ESLD = end-stage liver disease including cirrhosis; auto = auto-immune disease with immunosuppressive therapy; CHF = congestive heart failure; C. Dif. = recent or active treatment for C. Dif. colitis; h/o CVA = prior cerebrovascular accident; appi (recent) = recent appendicitis with ongoing antibiotic treatment. Systemic sx and Localizing sx: pertinent positives documented in ED provider note. Sx = symptoms; abd. = abdominal; +/− = ED documentation inconsistent; HA = headache; SOB = shortness of breath; fx = fracture; EKG Δ = ST segment elevations on electrocardiogram; RUQ = right upper quadrant of abdomen; MODS (from OSH) = transferred from outside hospital with multiple organ failure. ICU Dx: documented indication for antibiotic treatment following admission to the ICU. Chole = cholesystitis; uro = urosepsis; pna = pneumosepsis; empiric = antibiotics without identified source; line = indwelling vascular catheter infection.
Test Characteristics of SPoT and qSOFA Vital-Signs Criteria for Validation Cohort.
| 1° Outcome: ED Vasopressors, Direct ICU Admission, and Treatment for Infection | 2° Outcome: ICU Admission Within 24 hrs and Treatment for Infection | |||||||
|---|---|---|---|---|---|---|---|---|
| Triage Sensitivity | Time to (+) Screen | Sensitivitya | Specificitya | Positive Predictive Valuea | Sensitivitya | Specificitya | Positive Predictive Valuea | |
|
| ||||||||
| SPoT Vitals | 60% (45–74%)ǂ | 0.1 hours (0.0–0.8)* | 100% (93–100%)* | 89.1% (88.7–89.6%)¶ | 2.3% (1.7–3.0%)* | 73% (67–79%) | 89.6% (89.1–90.0%)¶ | 7.1% (6.1–8.3%)¶ |
| 30/50 | 50/50 | 17,488/19,620 | 50/2,182 | 155/212 | 17,431/19,458 | 155/2,182 | ||
| qSOFA Vitals | 28% (16–43%)ǂ | 0.7 hours (0.1–1.4)* | 86% (73–94%)* | 94.2% (93.8–94.5%)¶ | 3.6% (2.6–4.9%)* | 69% (62–75%) | 94.7% (94.4–95.0%)¶ | 12.4% (10.5–14.4%)¶ |
| 14/50 | 43/50 | 18,481/19,620 | 43/1,182 | 146/212 | 18,422/19,458 | 146/1,182 | ||
|
| ||||||||
| SPoT Vitals | 56% (41–70%)ǂ | 0.1 hours (0.0–0.8)* | 90% (78–97%) | 95.3% (95.0–95.6%)¶ | 4.7% (3.4–6.2%) | 63% (56–70%) | 95.7% (95.5–96.0%)¶ | 13.9% (11.8–16.3%)¶ |
| 28/50 | 45/50 | 18,704/19,620 | 45/961 | 134/212 | 18,631/19,458 | 134/961 | ||
| qSOFA Vitals | 28% (16–43%)ǂ | 0.7 hours (0.0–1.5)* | 80% (66–90%) | 97.0% (96.7–97.2%)¶ | 6.3% (4.5–8.5%) | 60% (53–67%) | 97.4% (97.2–97.6%)¶ | 20.0% (16.9–23.3%)¶ |
| 14/50 | 40/50 | 19,024/19,620 | 40/636 | 127/212 | 18,949/19,458 | 127/636 | ||
| SPoT Vitals | 50% (36–64%)ǂ | N/Ab | 80% (66–90%) | 98.5% (98.3–98.7%)¶ | 12.0% (8.7–16.0%) | 52% (45–59%) | 98.9% (98.7–99.0%)¶ | 33.3% (28.3–38.7%) |
| 25/50 | 40/50 | 19,327/19,620 | 40/333 | 111/212 | 19,236/19,458 | 111/333 | ||
| qSOFA Vitals | 24% (13–38%)ǂ | N/Ab | 70% (55–82%) | 98.9% (98.7–99.0%)¶ | 14.0% (9.9–18.9%) | 51% (44–57%) | 99.3% (99.1–99.4%)¶ | 42.8% (36.6–49.2%) |
| 12/50 | 35/50 | 19,405/19,620 | 35/250 | 107/212 | 19,315/19,458 | 107/250 | ||
Pairwise statistical comparisons of results for SPoT and qSOFA vital-signs criteria. For proportions, the percentages (and 95% confidence intervals) are shown above, as well as the raw counts for the relevant numerator and denominator in terms of ED subjects from the validation cohort. For times, the median (and interquartile range) are shown. For statistical tests-of-significance, we applied the McNemar exact conditional test for comparing sensitivities and specificities; the Fisher’s Exact Test for comparing positive predicative value; and the Wilcoxon signed-rank test for scalar results.
tCFI: triage criteria for infection (see Methods Section and Fig. 1 for details).
aBased on patients meeting vital-signs criteria at any time during ED course.
bAntibiotics & blood cultures are retrospective criteria for suspicion for infection as per Singer et al.[7] which cannot be applied for prospective sepsis screening/decision-making.
*Significant difference, p < 0.05, in pairwise comparison between SPoT Vitals and qSOFA vitals, within each section (I, II and III) above.
ǂSignificant difference, p < 0.01, in pairwise comparison between SPoT Vitals and qSOFA vitals, within each section (I, II and III) above.
¶Significant difference, p < 0.001, in pairwise comparison between SPoT Vitals and qSOFA vitals, within each section (I, II and III) above.